36Kr learned that Hezong Medicine Easy-To-Buy Pharmaceutical released its 2024 ESG report. The report shows that Hezong Medicine Easy-To-Buy Pharmaceutical has deeply integrated ESG concepts into its corporate development strategy, investing in areas such as national traditional Chinese medicine, special medical diets, medical equipment, and synthetic biology in the upstream of the industrial chain. In terms of extending downstream in the industrial chain, it has invested in empowering chain pharmacies, self-operated/franchised chain drugstores, O2O unmanned smart drug warehouses, online B2C e-commerce, O2O e-commerce, and various forms that directly reach the C-end. In addition, Hezong Medicine Easy-To-Buy Pharmaceutical continues to promote the construction of a green system, with its environmental protection investment in 2024 amounting to 70,900 yuan, recycling 153.5 tons of waste cardboard, and reducing water resource consumption by at least 20% year-on-year